A study published in JACC: Advances has found that a risk prediction algorithm incorporating HeartBeam Inc.'s (NASDAQ: BEAT) portable ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study, which evaluated 184 patients, showed that the algorithm achieved an area under the curve (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms. When a personal, symptom-free baseline ECG was available for comparison, the AUC rose to 92.9%, according to the company.
HeartBeam, a medical technology company focused on transforming cardiac care, said the results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program. The full press release is available at https://ibn.fm/ainxV.
The HeartBeam System is designed as a cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is intended for portable devices that can be used wherever the patient is, enabling physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. HeartBeam holds over 20 issued patents related to technology enablement.
The implications of this study are significant for emergency cardiac care. Chest pain is one of the most common reasons for emergency department visits, and accurate risk stratification is critical for timely treatment and resource allocation. By demonstrating that a portable, credit card-sized device combined with a risk algorithm can identify heart attack risk with high accuracy, HeartBeam's technology could potentially enable earlier detection and faster decision-making in both hospital and pre-hospital settings. The ability to compare with a personal baseline ECG further enhances accuracy, highlighting the value of longitudinal cardiac monitoring.
HeartBeam's approach aligns with the growing trend toward remote patient monitoring and point-of-care diagnostics. If cleared for heart attack detection, the system could become a valuable tool for paramedics, primary care physicians, and even patients themselves, providing actionable insights that could reduce time to treatment and improve outcomes. The company's technology has already received FDA clearance for arrhythmia assessment, and this study marks a step toward expanding its indications. For more information on HeartBeam's cleared indications for use, visit https://www.heartbeam.com/indications.
Investors and stakeholders can find the latest news and updates on HeartBeam at the company's newsroom: https://ibn.fm/BEAT.
